newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

  • Aligos Therapeutics initiated dosing in the Phase 1 study of investigational ASO ALG-170675 for chronic HBV infection.
  • The study is conducted in China by partner Amoytop, which holds rights in Greater China.
  • ALG-170675 is optimized for HBsAg RNA inhibition & immuno-activation with improved RNase H activity over bepirovirsen.
  • Novel monomers in ALG-170675 aim to reduce ASO toxicity & improve liver to kidney ratios.
  • The Phase 1 trial plans single & multiple ascending doses in approximately 56 healthy participants across four cohorts.
  • A cohort of approximately 16 participants with chronic HBV infection is expected to start in Q4 2026.
  • Future combination regimens may include ALG-170675, Amoytop's PEGBING®, & Aligos' pevifoscorvir sodium.
  • Aligos & Amoytop maintain a collaborative relationship to advance functional cure rates for chronic HBV patients.